A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects

Trial Profile

A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs ABY-039 (Primary) ; ABY-039 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors Affibody
  • Most Recent Events

    • 21 Mar 2018 Status changed from planning to recruiting, according to an Affibody media release.
    • 28 Feb 2018 New trial record
    • 23 Feb 2018 According to an Affibody media release, in January the UK regulatory agency MHRA approved the clinical trial application (CTA) for Phase I study with ABY-039.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top